Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle.
Staphylococcus aureus is one of the main etiological agents of bovine mastitis; however, antibiotics that are effective against bovine strains of S. aureus are not currently available. Staphylococcal enterotoxin type C (SEC), a superantigen, is the enterotoxin most frequently expressed by bovine strains of S. aureus and one of immunogenic determinants. The purpose of this study was to evaluate the protective effectiveness of recombinant SEC mutant vaccine (MastaVactrade mark) against experimentally induced bovine infection. Three representative SEC secreting strains were selected from 9 candidate isolates that showed various intensities of pathogenicity on mice and inoculated into 5 lactating dairy cattle at a concentration of 50-5.0x10(8) CFU per quarter. The optimal experimental bovine subclinical mastitis model was produced by inoculation with 50 CFU of S. aureus 409 per quarter, a level which was not lethal to mice. After the experimental model was determined, other 3 cattle were intramuscularly administered three doses of vaccine at day 0, at 2 wks and at 6 wks. Nine quarters of 3 vaccinated cattle and 8 quarters of 3 control cattle were then challenged with S. aureus 409. An SEC-specific ELISA test conducted at 4 wks post-immunization confirmed the presence of a high antibody titer against SEC in all vaccinated cattle. The somatic cell counts from the vaccinated group remained relatively low, whereas those of control group increased significantly after challenge with S. aureus. After challenge, S. aureus was not isolated from any cattle in the vaccinated group, whereas it was isolated from 75% of the cattle in the control group. These results indicate that recombinant SEC mutant vaccine had a protective effect against S. aureus intramammary infection in lactating cattle.
Chang
Byoung Sun
BS
Animal Health Research Institute, R&D Park, LG Life Sciences, Ltd., Daejeon, Republic of Korea.
Moon
Jin San
JS
Kang
Hyun-Mi
HM
Kim
Young-In
YI
Lee
Hong-Kyun
HK
Kim
Jong-Duk
JD
Lee
Byung-Saeng
BS
Koo
Hye Cheong
HC
Park
Yong Ho
YH
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000276:immunology; D002417:Cattle; D003612:Dairying; D004768:Enterotoxins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D008414:Mastitis, Bovine / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000276:immunology / Q000517:prevention & control* / Q000662:veterinary*; D013211:Staphylococcus aureus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification* / Q000472:pathogenicity; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000907:Antibodies, Bacterial; D004768:Enterotoxins; D014614:Vaccines, Synthetic; C034959:enterotoxin C, staphylococcal